公开(公告)号：HK1093973A1

公开(公告)日：2007-03-16

申请号：HK06113688

申请日：2006-12-13

Applicant: PORTOLA PHARM INC

Inventor： SCARBOROUGH ROBERT M ,  HUANG WOLIN ,  PANDEY ANJALI ,  BAUER SHAWN M ,  ZHANG XIAOMING ,  JIA ZHAOZHONG J

IPC: A61K20100101 ,  A61K31/517 ,  A61P20100101 ,  A61P7/02 ,  C07D20100101 ,  C07D409/12 ,  C07D409/14

Abstract: 2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds having the formula: wherein R is a member selected from the group consisting of H and C 1-6 alkyl; R 1 is a member selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-5 cycloalkyl and C 3-5 cycloalkyl-alkyl; R 2 is a member selected from the group consisting of H, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, cyano and -C(O)R 2a , wherein R 2a is a member selected from the group consisting of C 1-6 alkoxy and (C 1-6 alkyl) 0-2 amino; L is a 1 to 3 carbon linking group selected from the group consisting of -CH 2 -, -CH(CH 3 )-, -CH 2 CH 2 -, -CH 2 CH(CH 3 )- and -CH 2 CH 2 CH 2 -; L 1 is a linking group selected from the group consisting of a bond and -CH 2 -; L 2 is a linking group selected from the group consisting of a bond, -NH- and -CH 2 -; and Ar 1 is an aromatic ring selected from the group consisting of benzene, pyridine and pyrimidine; are provided. The compounds are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

公开(公告)号：CA2540214A1

公开(公告)日：2005-04-14

申请号：CA2540214

申请日：2004-09-29

Applicant: PORTOLA PHARM INC

Inventor： BAUER SHAWN M ,  PANDEY ANJALI ,  SCARBOROUGH ROBERT M ,  HUANG WOLIN ,  ZHANG XIAOMING ,  JIA ZHAOZHONG J

IPC: C07D409/12 ,  A61K20060101 ,  A61K31/517 ,  A61P7/02 ,  C07D409/14

Abstract: 2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds having the formula: wherein R is a member selected from the group consisting of H and C 1-6 alkyl; R 1 is a member selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-5 cycloalkyl and C 3-5 cycloalkyl-alkyl; R 2 is a member selected from the group consisting of H, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, cyano and -C(O)R 2a , wherein R 2a is a member selected from the group consisting of C 1-6 alkoxy and (C 1-6 alkyl) 0-2 amino; L is a 1 to 3 carbon linking group selected from the group consisting of -CH 2 -, -CH(CH 3 )-, -CH 2 CH 2 -, -CH 2 CH(CH 3 )- and -CH 2 CH 2 CH 2 -; L 1 is a linking group selected from the group consisting of a bond and -CH 2 -; L 2 is a linking group selected from the group consisting of a bond, -NH- and -CH 2 -; and Ar 1 is an aromatic ring selected from the group consisting of benzene, pyridine and pyrimidine; are provided. The compounds are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.